The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Drug discovery in the ubiquitin–proteasome system
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Live or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
Mechanisms Underlying Ubiquitination
Pickart, C. M. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.503 · Cited by 3,184
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
Cited by
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Self-citationRevisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688
Targeting Toll-like receptors: emerging therapeutics?
Hennessy, E. J., Parker, A. E., & O'Neill, L. A. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3203 · Cited by 886
TNF-α/NF-κB/Snail pathway in cancer cell migration and invasion
Wu, Y., & Zhou, B. P. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605530 · Cited by 798
The role of ubiquitination in tumorigenesis and targeted drug discovery
Deng, L., Meng, T., Chen, L., Wei, W., & Wang, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0107-0 · Cited by 744
Advancing targeted protein degradation for cancer therapy
Dale, B., Cheng, M., Park, K.-S., Kaniskan, H. Ü., Xiong, Y., & Jin, J. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00365-x · Cited by 632
Targeting the ubiquitin system in cancer therapy
Hoeller, D., & Dikic, I. (2009) · Nature · doi:10.1038/nature07960 · Cited by 599
Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Frezza, M., Hindo, S., Chen, D., Davenport, A., Schmitt, S., Tomco, D., & Ping Dou, Q. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791209009 · Cited by 552
Boutros, T., Chevet, E., & Metrakos, P. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.00106 · Cited by 545
Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Kupperman, E., Lee, E. C., Cao, Y., Bannerman, B., Fitzgerald, M., Berger, A., Yu, J., Yang, Y., Hales, P., Bruzzese, F., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2766 · Cited by 499
Self-citationTargeting Proteins for Destruction by the Ubiquitin System: Implications for Human Pathobiology
Schwartz, A. L., & Ciechanover, A. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.051208.165340 · Cited by 492
Global Protein Stability Profiling in Mammalian Cells
Yen, H.-C. S., Xu, Q., Chou, D. M., Zhao, Z., & Elledge, S. J. (2008) · Science · doi:10.1126/science.1160489 · Cited by 482
Brownell, J. E., Sintchak, M. D., Gavin, J. M., Liao, H., Bruzzese, F. J., Bump, N. J., Soucy, T. A., Milhollen, M. A., Yang, X., Burkhardt, A. L., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2009.12.024 · Cited by 464
Self-citationOerlemans, R., Franke, N. E., Assaraf, Y. G., Cloos, J., van Zantwijk, I., Berkers, C. R., Scheffer, G. L., Debipersad, K., Vojtekova, K., Lemos, C., et al. (2008) · Blood · doi:10.1182/blood-2007-08-104950 · Cited by 454
Inhibitors of Ubiquitin-Activating Enzyme (E1), a New Class of Potential Cancer Therapeutics
Yang, Y., Kitagaki, J., Dai, R.-M., Tsai, Y. C., Lorick, K. L., Ludwig, R. L., Pierre, S. A., Jensen, J. P., Davydov, I. V., Oberoi, P., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0568 · Cited by 441
Ubiquitin and ubiquitin-like proteins in cancer pathogenesis
Hoeller, D., Hecker, C.-M., & Dikic, I. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1994 · Cited by 408
Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes
Altun, M., Kramer, H. B., Willems, L. I., McDermott, J. L., Leach, C. A., Goldenberg, S. J., Kumar, K. G. S., Konietzny, R., Fischer, R., Kogan, E., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.08.018 · Cited by 402
Galdeano, C., Gadd, M. S., Soares, P., Scaffidi, S., Van Molle, I., Birced, I., Hewitt, S., Dias, D. M., & Ciulli, A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5011258 · Cited by 399
Targeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease
Edwards, M. R., Bartlett, N. W., Clarke, D., Birrell, M., Belvisi, M., & Johnston, S. L. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.09.003 · Cited by 375
“Polyubiquinated proteins are recognised by the proteasome which de-ubiquinates, unfolds and destroys the target protein (reviewed in Nalepa et al., 2006) .”
BackgroundLoor, J. J., Everts, R. E., Bionaz, M., Dann, H. M., Morin, D. E., Oliveira, R., Rodriguez-Zas, S. L., Drackley, J. K., & Lewin, H. A. (2007) · Physiological Genomics · doi:10.1152/physiolgenomics.00188.2007 · Cited by 365
Yamagishi, Y., Shoji, I., Miyagawa, S., Kawakami, T., Katoh, T., Goto, Y., & Suga, H. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.09.013 · Cited by 346
Building and remodelling Cullin–RING E3 ubiquitin ligases
Lydeard, J. R., Schulman, B. A., & Harper, J. W. (2013) · The EMBO Reports · doi:10.1038/embor.2013.173 · Cited by 327
Self-citationThe Role of the Selective Adaptor p62 and Ubiquitin-Like Proteins in Autophagy
Lippai, M., & Lőw, P. (2014) · BioMed Research International · doi:10.1155/2014/832704 · Cited by 322
Copper complexes as therapeutic agents
Duncan, C., & White, A. R. (2012) · Metallomics · doi:10.1039/c2mt00174h · Cited by 294
Small-Molecule Modulation of Protein Homeostasis
Burslem, G. M., & Crews, C. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00077 · Cited by 283
Cullin-RING Ligases as Attractive Anti-cancer Targets
Zhao, Y., & Sun, Y. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990300 · Cited by 278
Dou, Q., & Zonder, J. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140804154511 · Cited by 275
Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy
Dick, L. R., & Fleming, P. E. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.01.008 · Cited by 273
(2012) · doi:10.1158/0008-5472.can-12-0388 · Cited by 242
Maniaci, C., Hughes, S. J., Testa, A., Chen, W., Lamont, D. J., Rocha, S., Alessi, D. R., Romeo, R., & Ciulli, A. (2017) · Nature Communications · doi:10.1038/s41467-017-00954-1 · Cited by 245
Bulatov, E., & Ciulli, A. (2015) · Biochemical Journal · doi:10.1042/bj20141450 · Cited by 237
Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer
Soucy, T. A., Smith, P. G., & Rolfe, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0343 · Cited by 222
Self-citationThe NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy
Soucy, T. A., Dick, L. R., Smith, P. G., Milhollen, M. A., & Brownell, J. E. (2010) · Genes & Cancer · doi:10.1177/1947601910382898 · Cited by 225
Auxin Perception--Structural Insights
Calderon-Villalobos, L. I., Tan, X., Zheng, N., & Estelle, M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005546 · Cited by 177
Targeted degradation of transcription factors by TRAFTACs: TRAnscription Factor TArgeting Chimeras
Samarasinghe, K. T. G., Jaime-Figueroa, S., Burgess, M., Nalawansha, D. A., Dai, K., Hu, Z., Bebenek, A., Holley, S. A., & Crews, C. M. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.03.011 · Cited by 182
System-Wide Modulation of HECT E3 Ligases with Selective Ubiquitin Variant Probes
Zhang, W., Wu, K.-P., Sartori, M. A., Kamadurai, H. B., Ordureau, A., Jiang, C., Mercredi, P. Y., Murchie, R., Hu, J., Persaud, A., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.005 · Cited by 168
Self-citationFotheringham, S., Epping, M. T., Stimson, L., Khan, O., Wood, V., Pezzella, F., Bernards, R., & La Thangue, N. B. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.001 · Cited by 138
Targeting ubiquitin specific proteases for drug discovery
Daviet, L., & Colland, F. (2008) · Biochimie · doi:10.1016/j.biochi.2007.09.013 · Cited by 126
When worlds collide: IP3 receptors and the ERAD pathway
Wojcikiewicz, R. J. H., Pearce, M. M. P., Sliter, D. A., & Wang, Y. (2009) · Cell Calcium · doi:10.1016/j.ceca.2009.05.002 · Cited by 54
Chen, H., Chen, F., Liu, N., Wang, X., & Gou, S. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.09.005 · Cited by 51
Taymans, J.-M., Nkiliza, A., & Chartier-Harlin, M.-C. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.05.004 · Cited by 50
Epidermal growth factor receptor (EGFR) is a target of the tumor-suppressor E3 ligase FBXW7
Boretto, M., Geurts, M. H., Gandhi, S., Ma, Z., Staliarova, N., Celotti, M., Lim, S., He, G.-W., Millen, R., Driehuis, E., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2309902121 · Cited by 30
E3 ubiquitin ligases and human papillomavirus-induced carcinogenesis
Lou, Z., & Wang, S. (2014) · Journal of International Medical Research · doi:10.1177/0300060513506655 · Cited by 22
Metadata
- Authors
- Nalepa, G., Rolfe, M., & Harper, J. W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-07-01
- Volume
- 5
- Issue
- 7
- Pages
- 596-613
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1603251764
- Cited by
- 608
- References
- 163
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.